All In MedTech

FDA Clearance Tracker · P970051-S172

NUCLEUS 24 COCHLEAR IMPLANT SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 17, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 17, 2020

Approved

Time to decision

889 days

Received Oct 10, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P970051-S172
Device name
NUCLEUS 24 COCHLEAR IMPLANT SYSTEM
Applicant location
Lone Tree, CO
Received
Oct 10, 2017
Decided
Mar 17, 2020
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P970051

Device type

Device class
Class III

Every decision under product code MCM

FDA's approval statement

As written in FDA's record.

Approval for the IFU for Nucleus 24 Cochlear Implant System: 1) The Nucleus 24 Cochlear Implant System is intended for individuals 18 years of age or older who have bilateral, pre, peri or postlinguistic sensorineural hearing impairment and obtain limited benefit from appropriate binaural hearing aids.2) These individuals typically have moderate to profound hearing loss in the low frequencies and profound (>= 90 dB HL) hearing loss in the mid to high speech frequencies. Limited benefit from amplification is defined by test scores of 50% correct or less in the ear to be implanted (60% or less in the best-aided listening condition) on tape-recorded tests of open set sentence recognition.3) The Nucleus 24 cochlear implant system is intended for use in children 9 to 24 months of age who have bilateral profound sensorineural deafness and demonstrate limited benefit from appropriate binaural hearing aids.4) Children two years of age or older may demonstrate severe to profound hearing loss bilaterally.5) In younger children, limited benefit is defined as lack of progress in the development of simple auditory skills in conjunction with appropriate amplification and participation in intensive aural habilitation over a three to six-month period. It is recommended that limited benefit be quantified on a measure such as the Meaningful Auditory Integration Scale or the Early Speech Perception test.6) In older children, limited benefit is defined as <= 30% correct on the open set Multisyllabic Lexical Neighborhood Test (MLNT) or Lexical Neighborhood Test (LNT), depending upon the childs cognitive and linguistic skills. A three to six-month hearing aid trial is recommended for children without previous aided experience.

Source documents

Other decisions for Cochlear Americas

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.